Ichnos Sciences aims to shift the way the world thinks about innovation in medicine by developing potentially transformative biologic treatments in immuno-oncology. Headquartered in New York City, Ichnos has research and manufacturing operations at two sites in Switzerland. Ichnos has strong capabilities in research, antibody engineering and clinical development of biologics. The first wave of Ichnos’ multispecific antibody pipeline targeting a range of hematologic malignancies are in phase 1/2.